A recent study has revealed a potential embarrassing side effect associated with the use of GLP-1 agonists for diabetes treatment, indicating a higher likelihood of developing chronic cough among type 2 diabetes patients compared to those on other diabetes medications.
Recent research has identified a concerning side effect linked to GLP-1 agonists, which are commonly prescribed for managing diabetes and obesity. This study highlights that patients with type 2 diabetes using these medications may be at a greater risk of developing chronic coughs—specifically coughs that persist for over two months—compared to those receiving alternative diabetes treatments. Key medications in this category include Saxenda, Ozempic, Wegovy, and Mounjaro.
The study involved a substantial participant pool of 430,000 individuals diagnosed with type 2 diabetes who were treated with GLP-1 agonists, alongside 1.6 million patients on other diabetes treatments. Over a five-year follow-up period, chronic cough was reported to occur 10-30% more frequently among patients utilizing GLP-1 agonists. While the connection between these medications and the chronic cough is not extremely strong, researchers advise healthcare professionals to consider this possibility when encountering patients with ongoing coughs without clear explanations.
This discovery underscores the importance of monitoring patients on GLP-1 agonists for potential side effects, particularly as these medications are increasingly prescribed for weight management alongside diabetes treatment. It raises awareness about the need for further investigation into their effects and the implications for patient care, emphasizing that regular communication between patients and healthcare providers is crucial when assessing any side effects that arise during treatment.
